TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29325289

Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg/d for 208 weeks
Number of subjects: 188

Group type: COMPARATOR
Intervention: Telbivudine 0.6 g/d for 208 weeks
Number of subjects: 188
Study: 26053024

Group type: EXPERIMENTAL
Intervention: Nalmefene 18 mg
Number of subjects: 667

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study: 23490224

Group type: EXPERIMENTAL
Intervention: BEA2180 (50, 100 or 200 μg)
Number of subjects: 2080

Group type: EXPERIMENTAL
Intervention: Tiotropium (5 μg)
Number of subjects: 2080

Group type: EXPERIMENTAL
Intervention: BEA2180 (200 μg)
Number of subjects: 2080

Group type: EXPERIMENTAL
Intervention: BEA2180 (50 and 200 μg)
Number of subjects: 2080

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2080
Study: 21803584

Group type: EXPERIMENTAL
Intervention: Prosthetic foot condition with the most push-off
Number of subjects: 7

Group type: COMPARATOR
Intervention: Prosthetic foot condition with the least push-off
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Trailing prosthetic limb push-off impulse
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Prosthetic push-off work
Number of subjects: 7
Study: 19543908

Group type: EXPERIMENTAL
Intervention: Eccentric ergometer training (EET)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Conventional resistance training (RET)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cognitive training (CT)
Number of subjects: 62
Study: 16423664

Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging (DTI)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Epsilon imaging
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Strain rate (SR) imaging
Number of subjects: 5

Group type: COMPARATOR
Intervention: Conventional echocardiographic examination
Number of subjects: 5
Study: 15238405

Group type: EXPERIMENTAL
Intervention: Radiation plus cisplatin (study group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Radiation alone (control group)
Number of subjects: 44
Study: 11254234

Group type: EXPERIMENTAL
Intervention: Balneotherapy at the Dead Sea
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no balneotherapy)
Number of subjects: 48
Study: 9146850

Group type: EXPERIMENTAL
Intervention: Prednisolone (1.5 mg kg‐1)
Number of subjects: 10
Study: 7964943

Group type: EXPERIMENTAL
Intervention: UFT 350 mg/m2/d plus oral leucovorin 150 mg/d
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: UFT 300 mg/m2/d plus oral leucovorin 150 mg/d
Number of subjects: 45
Study: 3596338

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg at 2300 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine 1200 mg at 2300 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine 1600 mg at 2300 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine 400 mg bd (0800 h and 2300 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg at 1800 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine 1600 mg at 1800 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine 300 mg at 1800 h
Number of subjects: 0
Study: 29212965

Group type: EXPERIMENTAL
Intervention: 2 mg/day pitavastatin plus 10 mg/day ezetimibe
Number of subjects: 128

Group type: COMPARATOR
Intervention: 2 mg/day pitavastatin
Number of subjects: 128
Study: 27755389

Group type: EXPERIMENTAL
Intervention: Sequential nephron blockade
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Sequential renin-angiotensin system blockade
Number of subjects: 166

Group type: COMPARATOR
Intervention: Baseline (Resistant Hypertension)
Number of subjects: 166
Study: 25076372

Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (IOL) implantation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Limbal relaxing incisions (LRI)
Number of subjects: 31
Study: 23638126

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 250
Study: 20652797

Group type: EXPERIMENTAL
Intervention: Computer-designed structures
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waxed-up and digitized structures
Number of subjects: 60
Study: 18229990

Group type: EXPERIMENTAL
Intervention: Joint Attention (JA) intervention
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Symbolic Play (SP) intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 16368192

Group type: EXPERIMENTAL
Intervention: Brush-evoked allodynia
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal brushing
Number of subjects: 9
Study: 14600517

Group type: EXPERIMENTAL
Intervention: High-dose multiple micronutrient supplementation
Number of subjects: 481

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study: 10825334

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg IV (Group O4)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg IV (Group O8)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Saline IV (Group C)
Number of subjects: 82
Study: 8673938

Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (T group)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 110
Study: 1308714

Group type: COMPARATOR
Intervention: Booked mothers
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Unbooked mothers
Number of subjects: 391
Study: 6353843

Group type: EXPERIMENTAL
Intervention: Tranexamic acid treatment
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 112
Study: 31892352

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion at a rate of 0, 1, 2, 3, 5, or 8 IU h(‐ 1) for a total of 1 h
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion at increasing rates
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (0 IU h(‐ 1) infusion)
Number of subjects: 150
Study: 29737533

Group type: EXPERIMENTAL
Intervention: sutimlimab
Number of subjects: 64

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study: 26822403

Group type: EXPERIMENTAL
Intervention: Diode laser enucleation of the prostate (DiLEP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Plasmakinetic enucleation of the prostate (PKEP)
Number of subjects: 80
Study: 24929133

Group type: EXPERIMENTAL
Intervention: Multi-component integrated control strategy including bovine vaccination using a heterologous 'prime-boost' delivery platform based on the SjCTPI vaccine.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mass human chemotherapy and mollusciciding as part of the integrated strategy.
Number of subjects: 0
Study: 19826284

Group type: EXPERIMENTAL
Intervention: Swallow on the rings
Number of subjects: 6

Group type: COMPARATOR
Intervention: Counterweight exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dumbbells exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Barbell exercise
Number of subjects: 6
Study: 15076797

Group type: EXPERIMENTAL
Intervention: TriTrac-R3D monitors (TTM)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Self-reported activity measures
Number of subjects: 54

Group type: COMPARATOR
Intervention: TTM
Number of subjects: 54
Study: 11722852

Group type: EXPERIMENTAL
Intervention: Standard information plus group and repeated individual information (n=70)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard information plus brochure (n=70)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard information only (n=70)
Number of subjects: 210
Study: 9491040

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl, 15 to 20 microgram/kg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7887105

Group type: EXPERIMENTAL
Intervention: GA combined with epidural anaesthesia (GA+EPI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (EPI)
Number of subjects: 16
Study: 2964844

Group type: EXPERIMENTAL
Intervention: Glucagon-(1-21)-peptide
Number of subjects: 145

Group type: COMPARATOR
Intervention: Glucagon
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 11240090

Group type: EXPERIMENTAL
Intervention: Alfentanil infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (diphenhydramine)
Number of subjects: 12
Study: 31055640

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 30180236

Group type: EXPERIMENTAL
Intervention: L-arginine mouthwash
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: D-panthenol gel
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: D-panthenol mouthwash
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Topical application of corn oil gel (placebo)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Triester glycerol oxide gel
Number of subjects: 140

Group type: COMPARATOR
Intervention: Denture grinding (control)
Number of subjects: 140
Study: 27627073

Group type: EXPERIMENTAL
Intervention: GADA positive (GADA+) patients
Number of subjects: 625

Group type: COMPARATOR
Intervention: GADA negative (GADA-) patients
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Testing for GADA and C-peptide levels
Number of subjects: 625
Study: 24842806

Group type: EXPERIMENTAL
Intervention: Transient ovarian suspension
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (ovaries left free in the pelvis)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 22687788

Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate (SSRI)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 19
Study: 20091113

Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 17566094

Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 0
Study: 16060401

Group type: EXPERIMENTAL
Intervention: 200 mg gabapentin (100 mg, twice daily)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 400 mg gabapentin (100 mg, four times daily)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 600 mg gabapentin (200 mg, three times daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study: 12192247

Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: anti‐BLyS monoclonal antibody
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: anti‐CD40L monoclonal antibody
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: immunoablation techniques
Number of subjects: 0
Study: 10526722

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 165

Group type: COMPARATOR
Intervention: Human regular insulin
Number of subjects: 165
Study: 7477802

Group type: EXPERIMENTAL
Intervention: Combined cognitive-behavioral, nutritional and antidepressant therapy (5 with amineptine and 10 with fluvoxamine)
Number of subjects: 15
Study: 1800693

Group type: EXPERIMENTAL
Intervention: Dentures constructed on free plane articulators
Number of subjects: 7

Group type: COMPARATOR
Intervention: Dentures constructed on hinge articulators
Number of subjects: 7
Study: 7036932

Group type: EXPERIMENTAL
Intervention: Clofibrate (single oral dose)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 93
Study: 31480678

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group treatment (CBT) with development-specific topics for adolescents and young adults (YOUTH)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Age-unspecific CBT group intervention
Number of subjects: 266
Study: 27783275

Group type: EXPERIMENTAL
Intervention: BLR 250, BLR 350 (new peritoneal dialysis fluids)
Number of subjects: 211

Group type: COMPARATOR
Intervention: PD-4, PD-2 (standard peritoneal dialysis fluids)
Number of subjects: 211
Study: 25677397

Group type: EXPERIMENTAL
Intervention: Combined therapy with fluoxetine 20-40 mg/day plus interpersonal psychotherapy adapted to BPD (IPT-BPD) for 32 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combined therapy with fluoxetine 20-40 mg/day plus IPT-BPD
Number of subjects: 27
Study: 24322997

Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study: 21679182

Group type: EXPERIMENTAL
Intervention: High PCO2 solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.1 N HCl solution (acid perfusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison between NERD and healthy controls
Number of subjects: 20
Study: 19358119

Group type: EXPERIMENTAL
Intervention: Postoperative oral and nasal steroid therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Surgery only (historical control)
Number of subjects: 63
Study: 17953808

Group type: EXPERIMENTAL
Intervention: Vitamin B12, folic acid, L-carnitine, and betaine supplementation
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combined MMA with homocysteinemia
Number of subjects: 57
Study: 15359637

Group type: EXPERIMENTAL
Intervention: Radiotherapy (involved fields, 40 Gy)
Number of subjects: 341

Group type: COMPARATOR
Intervention: No radiotherapy (control group)
Number of subjects: 341
Study: 12363058

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Coadministered AQ+SP
Number of subjects: 351
Study: 9723820

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8123489

Group type: EXPERIMENTAL
Intervention: 500 U of recombinant interleukin 2 (IL‐2)
Number of subjects: 31

Group type: COMPARATOR
Intervention: 500,000 U of recombinant interleukin 2 (IL‐2)
Number of subjects: 31
Study: 2678805

Group type: EXPERIMENTAL
Intervention: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 600 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 900 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 1200 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 1500 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1170119

Group type: EXPERIMENTAL
Intervention: Insulin 0.05 μ/kg body weight injected intravenously at 8 a.m.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Insulin 0.05 μ/kg body weight injected intravenously at 5 p.m.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Insulin injection in the afternoon vs morning
Number of subjects: 14

Group type: COMPARATOR
Intervention: Caloric change in plasma after insulin injection
Number of subjects: 14

Group type: COMPARATOR
Intervention: Plasma growth hormone response
Number of subjects: 14
Study: 31809392

Group type: EXPERIMENTAL
Intervention: Mentored PriCARE
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: PriCARE
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 30555044

Group type: EXPERIMENTAL
Intervention: Small colorectal polyps with at least one cancer associated event (CAE)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Small colorectal polyps with ≥2 mutations
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Small colorectal polyps that regressed
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: All samples analyzed for MMR proficiency
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Small colorectal polyps with CIMP analysis
Number of subjects: 68
Study: 28331291

Group type: EXPERIMENTAL
Intervention: DA-8031 at doses of 5, 10, 20, 40, 60, 80, or 120 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DA-8031 (80 mg or less)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26385201

Group type: EXPERIMENTAL
Intervention: Cannabis (12.5% tetrahydrocannabinol), median daily dose of 2.5 g/d
Number of subjects: 431

Group type: COMPARATOR
Intervention: Control (no cannabis use)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Cannabis
Number of subjects: 431
Study: 22790513

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (Avastin) with Ahmed valve implantation and panretinal photocoagulation (PRP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ahmed valve implantation with panretinal photocoagulation (PRP) (control group)
Number of subjects: 40
Study: 22046230

Group type: COMPARATOR
Intervention: Informed consent comprehension quiz administered at enrollment and during follow-up
Number of subjects: 1835
Study: 18164467

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study: 17123192

Group type: EXPERIMENTAL
Intervention: Immediate training (IT) for new HA users; 8 weeks of at-home syllable identification training and in-laboratory testing.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed training (DT) for new HA users; identical in-laboratory testing without training initially, followed by training after initial testing.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training for experienced HA users; identical training and testing procedures as new HA users.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training-related improvements for both new and experienced HA users.
Number of subjects: 0
Study: 14580826

Group type: EXPERIMENTAL
Intervention: Immediate loading in an orthosis
Number of subjects: 28

Group type: COMPARATOR
Intervention: Traditional serial plaster casting
Number of subjects: 28
Study: 11053903

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 300 mg/24 h
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg/12 h
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 300 mg/24 h plus cefepime 2 g/12 h
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg/12 h plus cefepime 2 g/12 h
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Combination regimens (both)
Number of subjects: 3
Study: 9253781

Group type: EXPERIMENTAL
Intervention: Standard packed red blood cell (RBC) transfusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leukocyte-depleted red blood cell (RBC) transfusions
Number of subjects: 0
Study: 8290662

Group type: EXPERIMENTAL
Intervention: Maintenance antidepressants
Number of subjects: 300

Group type: COMPARATOR
Intervention: Drug treatment
Number of subjects: 300
Study: 3944373

Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate aerosol (1050 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isoproterenol (255 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31439640

Group type: EXPERIMENTAL
Intervention: 2‐chloroprocaine
Number of subjects: 150

Group type: COMPARATOR
Intervention: prilocaine
Number of subjects: 150
Study: 28192588

Group type: EXPERIMENTAL
Intervention: 70° side-cut
Number of subjects: 29

Group type: COMPARATOR
Intervention: 115° side-cut
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups (70° and 115° side-cuts)
Number of subjects: 29
Study: 26068110

Group type: EXPERIMENTAL
Intervention: Tight glycaemic control
Number of subjects: 41

Group type: COMPARATOR
Intervention: Exogenous insulin delivery
Number of subjects: 41
Study: 24411753

Group type: EXPERIMENTAL
Intervention: 12-week behavioral weight loss intervention
Number of subjects: 132
Study: 23199586

Group type: EXPERIMENTAL
Intervention: Nitrofurazone-impregnated silicone catheter
Number of subjects: 7102

Group type: EXPERIMENTAL
Intervention: Silver alloy-coated hydrogel latex catheter
Number of subjects: 7102

Group type: COMPARATOR
Intervention: PTFE-coated latex catheter
Number of subjects: 7102
Study: 18983947

Group type: EXPERIMENTAL
Intervention: PTH(1-84) for 18 months
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PTH(1-84) for 24 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17526462

Group type: EXPERIMENTAL
Intervention: tobramycin 0.3%/dexamethasone 0.1%
Number of subjects: 40

Group type: COMPARATOR
Intervention: tobramycin 0.3%/loteprednol 0.5%
Number of subjects: 40
Study: 14620389

Group type: EXPERIMENTAL
Intervention: Filgrastim 5 microg/kg given once/day
Number of subjects: 222
Study: 10852359

Group type: EXPERIMENTAL
Intervention: Expressed desire for treatment
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Eligibility for methadone maintenance
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Two or more previous treatment admissions
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Frequency of injection
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Heroin use in the past 30 days
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Being HIV positive
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Giving money or drugs for sex
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Level of injection-related risk for HIV infection
Number of subjects: 823
Study: 8614420

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by radiation therapy
Number of subjects: 244

Group type: COMPARATOR
Intervention: Radiation therapy followed by chemotherapy
Number of subjects: 244
Study: 1477397

Group type: EXPERIMENTAL
Intervention: Physical activity at work
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Leisure time physical activities
Number of subjects: 577
Study: 6383269

Group type: EXPERIMENTAL
Intervention: LYCD ointment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ointment base (Control)
Number of subjects: 9
Study: 2880362

Group type: EXPERIMENTAL
Intervention: Perphenazine (20.5 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Haloperidol (5.5 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Haloperidol (11 mg/day) + Biperiden (7 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Chlorprothixene (142 mg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 31743982

Group type: EXPERIMENTAL
Intervention: Technological proprioceptive rehabilitation (TG)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional rehabilitation (CG)
Number of subjects: 64